Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJLSG1902 atezolizumab + carboplatin + pemetrexed in elderly advanced non-squamous NSCLC
jRCTs041200032Phase 2Completed
- Sponsor
- Central Japan Lung Study Group
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin and pemetrexed in Non-small cell lung cancer (NS-NSCLC), sponsored by Central Japan Lung Study Group. Primary endpoint: Progression-free survival. Started Jul 2020; status: completed.
02
Drugs
atezolizumabcarboplatinpemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs041200032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200032.